Compare Life Time Group Holdings Inc. Common Stock (LTH) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Life Time Group Holdings Inc. Common Stock vs Repligen Corporation Common Stock — how do they compare? Life Time Group Holdings Inc. Common Stock trades at $40.07 (market cap $8.86B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Life Time Group Holdings Inc. Common Stock is more actively traded (3,372,885 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold Life Time Group Holdings Inc. Common Stock for 6 Days and Repligen Corporation Common Stock for 0 Days on average.
| LTH | RGEN | |
|---|---|---|
Market Cap | $8.86B | $11.14B |
Volume | 3,372,885 | 1,259,263 |
Sector | Consumer Cyclical | Health |
52-Week High | $45.73 | $194.57 |
52-Week Low | $24.59 | $102.87 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $12.91B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Life Time Group Holdings (LTH) trades at $39.66, down 1.76% today, amid bullish technical signals and strong fundamental performance. The stock shows consistent earnings beats, with Q2 2026 EPS of $0.48 exceeding expectations by 28%. Recent expansion news includes new athletic clubs in Florida and Boston, highlighting growth initiatives. Analyst consensus remains strongly bullish with an 86.7% buy rating and $55.17 price target, implying 39% upside.
LTH presents a compelling growth story with expanding facilities and robust profitability margins. Key risks include execution of expansion plans and consumer discretionary spending sensitivity. The valuation at 21.7x P/E appears reasonable given 13% net margins and double-digit ROE. Near-term catalyst is Q3 2026 earnings on October 29, 2026, which could validate the bullish analyst outlook.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Life Time Group Holdings Inc. Common Stock
Life Time operates fitness and lifestyle centers that offer gyms, classes, sports facilities, and wellness services.
Read more on LTH →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
